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Increasing Minority Enrollment Onto Clinical Trials: Practical
Strategies and Challenges Emerge From the NRG Oncology
Accrual Workshop
By Sandra E. Brooks, MD, MBA, Carolyn Y. Muller, MD, William Robinson, MD, Eleanor M. Walker, MD,
Kate Yeager, RN, PhD, Elise D. Cook, MD, MS, Sue Friedman, DVM, Carol P. Somkin, PhD,
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Abstract
Racial and ethnic diversity has historically been difficult to achieve
in National Cancer Institute–sponsored clinical trials, even while
as many as 80% of those trials have faced difficulty in meeting
overall recruitment targets. In an attempt to address these
issues, NRG Oncology recently convened a comprehensive
workshop titled “Clinical Trials Enrollment: Challenges and Opportunities.” Discussants at the workshop included representatives of the three legacy groups of the NRG (ie, Gynecologic
Oncology Group, National Surgical Adjuvant Breast and Bowel
Program, and Radiation Therapy Oncology Group), a minoritybased community clinical oncology program, a large integrated
health care system, the leadership of the National Cancer Institute, and a large patient advocacy group. This article summarizes
the concepts discussed at the workshop, which included: needs

Introduction
Clinical trials supported by the National Cancer Institute
(NCI) cooperative group clinical trials mechanism have been
instrumental in advancing the most important paradigmchanging findings from randomized phase III trials. However,
the reality of federal budget limitations, along with emerging
concepts of personalized health care, prompted the Institute of
Medicine (IOM) to evaluate the cost and sustainability of the
cooperative group program. In 2009, the IOM made consensus
recommendations designed to improve cancer clinical trials,
which called for the merger and/or consolidation of the cooperative groups.1 A subsequent workshop recommended implementation steps to increase the speed, volume, and diversity of
patient accrual.2
The science of clinical trial accrual, particularly analysis of
participant diversity, is an area of much-needed study.3-5 The
IOM noted that despite programs such as minority-based community clinical oncology programs (MB-CCOPs) and patient
navigator research programs, racial disparities in enrollment
persist.6
In an effort to examine clinical trial accrual, and specifically
to develop new ideas for improving the accrual of racial and
ethnic minorities, the newly formed NRG Oncology (consoli486
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assessments, infrastructural support, training of investigators
and research staff, specific clinical trial recruitment strategies
(both system and community based), and development and
mentoring of young investigators. Many new, more specific
tactics, including use of diverse cancer care settings, direct-toconsumer communication, and the need for centralized information technology such as the use of software to match trials to
special populations, are presented. It was concluded that new,
innovative trial designs and the realities of limited funding would
require the adoption of effective and efficient recruiting strategies, specialized training, and stakeholder engagement. US clinical research programs must generate and embrace new ideas
and pilot test novel recruitment strategies if they are to maintain
their historic role as world leaders in cancer care innovation and
delivery.

dation of Gynecologic Oncology Group [GOG], National Surgical Adjuvant Breast and Bowel Program [NSABP], and
Radiation Therapy Oncology Group [RTOG]) sponsored a
workshop entitled “Clinical Trial Enrollment: Challenges and
Opportunities” during the inaugural NRG semiannual meeting. Participants included representatives of three of the NCI
legacy groups (ie, NSABP, RTOG, and GOG), an MB-CCOP,
a large national health care system, patient advocacy leaders,
and NCI Community Oncology Research Program (NCORP)
leadership. This article explores barriers and opportunities to
address clinical trial enrollment within the context of NRG
Oncology.

Barriers to Clinical Trial Accrual
Cooperative Groups Address Problem
GOG investigators presented findings from a recent study examining patient and physician factors associated with clinical
trial accrual for women with gynecologic cancers. This prospective, observational study sought to identify modifiable factors
related to availability, eligibility, and enrollment in GOG cervical and uterine cancer trials and included 150 physicians and
781 patients from 60 sites from across the United States.7 Fac-
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tors associated with patient enrollment onto therapeutic trials
included: belief that the trial might help, patients’ concern
about their care if they were not in a trial, and patients’ perception of pressure from their provider to enroll onto a trial. Significant physician beliefs associated with enrollment were:
believing patients would not do well with standard therapy and
belief the trial would not be time consuming. Nonwhite patients and patients of black physicians (irrespective of race) had
higher odds of enrolling onto clinical trials compared with
other patients. The authors concluded that interventions designed to address the consent process, patient and physician
understanding of beliefs, cultural factors, and trust could improve enrollment onto cancer clinical trials.
RTOG investigators also conducted a study to assess attitudes, beliefs, and practices of principal investigators and clinical research associates that might influence clinical trial accrual
at 267 member institutions.8 Specific barriers included large
time commitments for the participants, insurance coverage,
lack of family support, fear of toxicity, and preference for a
particular type of therapy. Nearly one third of the staff indicated there was no formal mechanism for screening patients for
eligibility for a trial and that translated consents were needed for
non-English speakers. Analysis of the data led to the following
recommendations: development of scripts to reduce the potential for bias, creation of training modules for principal investigators and clinical research assistants, and expansion of patient
navigator programs.
The RTOG team used these findings to create a cultural
competency training program that recognizes the importance of
cultural diversity, awareness, sensitivity, and competence
among health care providers and investigators.9 Guided by this
model, investigators created a four-module 3.5-hour training
program that focused on barriers, myths, beliefs, and norms
regarding clinical trials within Latino and African American
cultures.10 The modules contain role-playing examples of patient discussions. Assessment of this program is ongoing.11
NSABP representatives reported on the Diversity Strategic
Planning Working Group (DSPWG), designed to enhance minority participation through education of investigators, research staff, and community groups, and the establishment of
relationships with minority organizations. The DSPWG provided culturally sensitive input during the development phase
of protocols and made recommendations regarding the need for
targeting certain populations for accrual. The DSPWG additionally created a resource list of culturally appropriate educational information about clinical trials and conducted special
educational sessions on cultural competency at NSABP group
meetings.
Recognizing that a diverse research workforce is pivotal to a
holistic strategy for recruitment of underserved populations,
the DSPWG developed a junior minority investigator travel
award to encourage young investigators and a minority mentoring program to facilitate collaboration of junior minority
investigators with senior investigators. Incorporation of these
best practices is currently being explored by the NRG Health
Disparities Committee.
Copyright © 2015 by American Society of Clinical Oncology

Large Health Care System Addresses Problem
Kaiser Permanente of Northern California (KPNC) recently
examined structural features that facilitate clinical trial accrual
in general and among minority and underserved populations.
This large, integrated health care delivery system has 3.5 million
members, which represents approximately 35% of the northern
California health care market and 1% of the US cancer burden.
Furthermore, the insured membership of KPNC reflects the
insured population in the geographic area it serves in terms of
age, race/ethnicity, and socioeconomic status.12
Of great importance, members with cancer receive virtually
all of their care in a coordinated fashion from KPNC physicians
at community medical centers, where the workforce reflects the
diversity of their locations.13 The provision of coordinated care,
along with the use of a system-wide comprehensive electronic
medical record and associated research databases and a widely
disseminated clinical trials program, has reduced disparate clinical trial enrollment by race/ethnicity. This is consistent with
other research that has shown that integration of care serves to
reduce racial/ethnic disparities in cancer outcomes.14
KPNC recently completed “CHOICES: Understanding
Clinical Trials As a Treatment Option” to evaluate barriers to
trials among oncologists and patients as part of this effort. Patients who participated in CHOICES (N ⫽ 905) were eligible
for a breast, colorectal, or lung NCI cooperative group trial
being conducted at KPNC. A survey, which assessed KPNC
oncologists’ (N ⫽ 88) attitudes, demographics, and trial experience, revealed that oncologists’ awareness of open trials, their
willingness to discuss trials with eligible patients, and their perception of the organizational value of clinical trial activity were
strong predictors of their subsequent trial accrual.15

MB-CCOP Addresses Problem
In 1983, the NCI created the MB-CCOP to address minority
recruitment to clinical trials, serving as a laboratory for testing
enrollment strategies.16 Leadership from the MB-CCOP based
at Tulane University in Louisiana indicated the most consistently successful strategies included: use of culturally sensitive
investigators and coordinators, incorporation of a community
advisory board, and partnership with local churches, community groups, and language-based media outlets on an ongoing
basis (Table 1).
In addition, investigators from this large, inner-city MBCCOP reported a recent study of factors affecting enrollment of
women with cervical cancer onto clinical trials. The most important factor was patients’ perception of the degree of commitment of the primary oncologist to the trial.17

Patient Advocate/Consumer Addresses Problem
A cancer survivor with extensive experience in leading patient
advocacy work presented concerns regarding clinical trial accrual drawn from her constituency. Noting that an increasing
number of trials target specific molecular characteristics of individual cancers, the patient advocate noted that such targeted
therapy studies may compete with larger, more accessible trials
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Table 1. Partnerships to Address Minority Recruitment to Clinical Trials
Partner

Target Audience

Description

Helping Hands Across the Divide churches

African American

Health promotion–related collaboration and clinical
trial education

Vietnamese–US Representative Louisiana Department
of Wildlife and Fisheries field offices

Vietnamese

Health promotion

Spanish language news, television, and radio

Hispanic/Latino populations, largely Honduran

Clinical trial information

NCI Leadership Addresses Problem
From the perspective of the NCI, it is vitally important that
participation in clinical trials is sufficient to support novel trial
designs and inclusive enough to translate scientific advances to
the general population. Figure 1 demonstrates that although
there has been some increase in enrollment of minority populations onto clinical trials over the past decade, there remains
substantial opportunity for improvement.
In August 2014, the NCI launched a new community-based
research program that expanded the scope of clinical trials to
include cancer care delivery research. This provides an opportunity to explore the multilevel influences of providers and
organizations on the enrollment of minority and underserved
patients onto clinical trials.
488
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The structure of this new program—the NCI Community
Oncology Research Program (NCORP)— encourages trialbased recruitment networks for large clinical trials (eg, phase III
chemoprevention and screening trials) and perhaps most importantly includes additional funding, including supplements
for navigators or other specifically needed local personnel. To
further enhance accessibility of trials, the NCI is also currently
seeking ways to support research bases in translating consents
for the multitude of languages spoken within the NCI National
Clinical Trials Network.

Strategies for Enhancing Clinical Trial
Enrollment and Plans for the Future
The concepts presented and discussed at this workshop covered
diverse aspects of poor enrollment and disparity in accrual to
clinical trials. A number of common themes emerged.
First, novel trial designs using targeted agents with biomarker end points will become standard. These designs will
naturally create subgroups from larger disease populations. Targeted recruitment and emphasis on the personalized nature of
such trials may facilitate accrual to these specialized studies.
Inclusion of diverse subgroups should be considered during the
trial design phase. Review of protocols in development using a
disparity lens will lessen the potential for future problems.

50,000

No. of Patients Enrolled

with wider eligibility. Patients or their physicians may not be
aware of or have access to the more targeted studies, which may
then affect enrollment onto those studies.
An example would include poly (ADP-ribose) polymerase
inhibitor studies that focus on individuals with BRCA mutations, which account for approximately 7% and 15% of all
women with breast and ovarian malignancies, respectively.
These studies have the potential to compete directly with more
numerous breast and ovarian cancer trials.
To further illustrate, a recent search of ClinicalTrials.gov for
treatment studies of advanced breast cancer revealed 181 studies open to women with advanced breast cancer: 36 studies for
advanced estrogen receptor– and progesterone receptor–positive breast cancer (common in women with BRCA2 mutations)
and 29 studies for women with advanced triple-negative breast
cancer (common in women with BRCA1 mutations). The five
studies open specifically for women with advanced BRCAassociated breast cancer were thus competing with all of these
other studies. The prospect of being unable to complete BRCAspecific clinical trials jeopardizes progress in treating these cancers. Furthermore, it could seriously threaten the viability of
targeted therapy research. A more comprehensive approach
(and less confusing for patients) would include both physician/
investigator-based and patient/consumer-based strategies. Physicians and investigators would benefit from prioritization of
studies focused on limited population groups and financial or
other encouragement to refer patients to targeted therapy trials.
Approaches that are patient (or consumer) friendly would include direct education, clinical trial matching services, and
use of advocacy groups, such as FORCE (Facing Our Risk of
Cancer Empowered), which currently sponsors several such
programs.18
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Figure 1. Minority enrollment onto National Cancer Institute–funded
trials from 2003 to 2013. Minority indicates nonwhite race or Hispanic
ethnicity; majority indicates white race and non-Hispanic ethnicity. Data
adapted with permission.
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Second, novel trial design using agents targeted at the molecular level could lessen the need to define a study population
as homogenous based on traditional, less precise eligibility criteria. Rather, individuals will be defined by their personal molecular (genomic) structure, which will in turn determine their
eligibility for a specific trial.
Third, the influence of local health care payers/insurers on
the delivery of cancer care must be evaluated in much more
detail than it has been to date. Cancer care delivery research
must be made available at both the community and academic
levels to best develop interventions designed to improve health
outcomes. Organized study of these concepts will likely require
modifications in process, including an examination of the consent process, to facilitate this research.
Fourth, the commitment of the physician/investigator is
paramount. Investigators must be culturally sensitive and aware
of the impact of appropriate communication and patient trust.
Above all, they must believe in the importance of clinical research and be committed to enrollment and possess the ability
to encourage diverse groups of patients to also believe and participate in clinical trials. The cooperative groups are well positioned to address this need by designing ongoing training
programs for investigators, particularly junior investigators who
are available to all groups and stakeholders involved in clinical
trials participation.
Fifth, direct-to-patient (consumer) communication/advertising must become more widespread. Collaboration with key
stakeholders such as community groups, survivor advocacy
groups, churches, and other local institutions can include
novel approaches to facilitate accrual of underrepresented
populations. The NCORP places increased emphasis on
cancer prevention trials and studies of chronic toxicities,
both of which are particularly well served by direct-to-community messaging.
Sixth, local institutional commitment and adequate infrastructure including translation of consents, navigator programs,
and research friendly electronic medical records provide examples of such support.
Seventh, expansion and standardization of demographic
data collection and capture of real-time information about accruals relative to the burden of disease in special populations
should also be priorities. The NRG Oncology Health Disparities Committee is currently evaluating this issue. In addition to
standardized collection of race/ethnicity and sex, country of
origin, sexual orientation, veteran status, and income data are
being discussed.
Eighth, strengthened information technology infrastructure
and direct interface with existing national and local databases
should occur.

Ninth, recruitment, training, and mentorship of young investigators interested in clinical research, particularly those of
ethnic minority backgrounds and/or those with an interest in
cancer disparities, must be more fully developed. Existing local
educational programs may serve as models for larger efforts
from the cooperative groups or directly from the NCI.
Tenth, underlying all of this is the need for continued and
improved budgetary support for clinical cancer research within
the NCI by Congress.
This workshop was the direct responsibility of the NRG
Health Disparities Committee, which is charged with developing strategies to increase enrollment of minorities and the
underserved onto clinical trials. The committee includes experienced investigators from a wide range of disciplines and backgrounds and is chaired by representatives of the three legacy
groups (ie, GOG, RTOG, and NSABP). The committee plans
to incorporate the best practices presented at this workshop
through involvement in disease site committees, input into
protocol development, analysis of educational workshops, development of mentoring programs, and dissemination of information and research.
The workshop described represents an initial step in this
direction by combining the collective experience and potential
of the new NRG Oncology Group and the NCI to enhance
clinical trial accrual. Moving forward, input will be solicited
from a wide array of stakeholders, including community investigators, the patient advocate community, and basic science
researchers. This will be essential for these trials to ultimately
improve the quality of cancer care.
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Order the ASCO Answers Palliative Care Booklet for Patients
and Their Families
Cancer and its treatment often cause discomfort and challenges that greatly affect a
person’s life and well-being. Cancer.Net’s ASCO Answers Palliative Care Booklet
contains trusted information on how palliative care is used to manage symptoms and
side effects, how to provide support to family, friends, and caregivers, how to access
palliative care services, and more. Order the booklet in quantities of 125 for your practice
at cancer.net/estore.
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